Literature DB >> 30106846

Next Generation Sequencing of Sporadic Vestibular Schwannoma: Necessity of Biallelic NF2 Inactivation and Implications of Accessory Non-NF2 Variants.

Matthew L Carlson1,2, James B Smadbeck3, Michael J Link2,1, Eric W Klee3, George Vasmatzis3, Lisa A Schimmenti1.   

Abstract

OBJECTIVES: 1) Describe the genetic alterations discovered in a series of sporadic vestibular schwannomas (VS). 2) Identify if more clinically aggressive variants possess different genetic alterations compared to more indolent-behaving VS.
METHODS: Fresh frozen tumor and matched peripheral blood leukocytes from 23 individuals with sporadic VS were analyzed using whole-exome sequencing, tumor whole transcriptome expression profiling (mRNA-Seq), and tumor mate-pair analysis. Source cases included tumors with fast preoperative growth, giant tumors in young patients, tumors with macrocystic change, recurrent tumors following radiation or microsurgery, and indolent small tumors with minimal or no growth before surgery. Somatic and germ-line alterations of the NF2 gene and beyond the NF2 locus were identified and analyzed using complementing analyses.
RESULTS: Biallelic somatic events involving the NF2 gene were discovered in every analyzed tumor specimen with no concurrent NF2 variants identified in matching peripheral blood specimens. Thirteen tumors showed loss of one chromosome 22 (ch22), 4 tumors showed copy-neutral 22q loss of heterozygosity, and 31 unique small variants in the NF2 gene were discovered. Of the latter, 10 were essential splice site, 11 frame shift, 7 stop gain, 2 missense, and 1 in-frame mutation. No other common or recurring NF2 mutations were identified. However, several other notable large chromosomal aberrations were discovered including 2 tumors with loss of a chromosome 21, 3 with loss of an X or Y chromosome, 1 with copy-neutral loss of heterozygosity in chromosome 15, and 1 with loss of 18p and 16q. All of these other major chromosomal abnormalities only occurred in tumors demonstrating a more aggressive phenotype.
CONCLUSIONS: To date, few studies have used whole-exome sequencing, mate-pair analysis, and RNA-seq to profile genome-wide alterations in sporadic VS. Using high-throughput deep sequencing, "two-hit" alterations in the NF2 gene were identified in every tumor and were not present in peripheral blood supporting that all events were somatic. Type of NF2 gene alteration and accessory mutations outside the NF2 locus may predict phenotypic expression and clinical course.

Entities:  

Mesh:

Year:  2018        PMID: 30106846     DOI: 10.1097/MAO.0000000000001932

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  11 in total

1.  Koos grade IV vestibular schwannomas: considerations on a consecutive series of 60 cases-searching for the balance between preservation of function and maximal tumor removal.

Authors:  Luciano Mastronardi; Alberto Campione; Fabio Boccacci; Carlo Giacobbo Scavo; Ettore Carpineta; Guglielmo Cacciotti; Raffaelino Roperto; Albert Sufianov; Ali Zomorodi
Journal:  Neurosurg Rev       Date:  2021-02-18       Impact factor: 3.042

2.  Microsurgical treatment of symptomatic vestibular schwannomas in patients under 40: different results before and after age of 30.

Authors:  Luciano Mastronardi; Alberto Campione; Guglielmo Cacciotti; Ettore Carpineta; Carlo Giacobbo Scavo; Raffaele Roperto; Giovanni Stati; Albert A Sufianov; Karl Schaller
Journal:  Neurosurg Rev       Date:  2021-08-17       Impact factor: 3.042

3.  A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.

Authors:  Chay Paterson; Ivana Bozic; Miriam J Smith; Xanthe Hoad; D Gareth R Evans
Journal:  Br J Cancer       Date:  2022-09-12       Impact factor: 9.075

Review 4.  Diagnostic Pathology of Tumors of Peripheral Nerve.

Authors:  Sarra M Belakhoua; Fausto J Rodriguez
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

Review 5.  Applications of single-cell sequencing for the field of otolaryngology: A contemporary review.

Authors:  Madeline P Pyle; Michael Hoa
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-04-27

6.  Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base section.

Authors:  Daniele Starnoni; Lorenzo Giammattei; Giulia Cossu; Michael J Link; Pierre-Hugues Roche; Ari G Chacko; Kenji Ohata; Majid Samii; Ashish Suri; Michael Bruneau; Jan F Cornelius; Luigi Cavallo; Torstein R Meling; Sebastien Froelich; Marcos Tatagiba; Albert Sufianov; Dimitrios Paraskevopoulos; Idoya Zazpe; Moncef Berhouma; Emmanuel Jouanneau; Jeroen B Verheul; Constantin Tuleasca; Mercy George; Marc Levivier; Mahmoud Messerer; Roy Thomas Daniel
Journal:  Acta Neurochir (Wien)       Date:  2020-07-29       Impact factor: 2.216

Review 7.  Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.

Authors:  Suha Bachir; Sanjit Shah; Scott Shapiro; Abigail Koehler; Abdelkader Mahammedi; Ravi N Samy; Mario Zuccarello; Elizabeth Schorry; Soma Sengupta
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

8.  Gamma Knife Radiosurgery does not alter the copy number aberration profile in sporadic vestibular schwannoma.

Authors:  Morten Lund-Johansen; Per-Morten Knappskog; Aril Løge Håvik; Ove Bruland; Dhanushan Dhayalan
Journal:  J Neurooncol       Date:  2020-09-27       Impact factor: 4.130

9.  Whole Genome Sequencing Identifies Key Genes in Spinal Schwannoma.

Authors:  Xin Gao; Li Zhang; Qi Jia; Liang Tang; Wen Guo; Tao Wang; Zheyu Wu; Wang Zhou; Zhenxi Li; Jianru Xiao
Journal:  Front Genet       Date:  2020-10-30       Impact factor: 4.599

10.  The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients.

Authors:  Peter Taule-Sivertsen; Ove Bruland; Aril Løge Håvik; Eirik Bratland; Morten Lund-Johansen; Per Morten Knappskog
Journal:  J Neurooncol       Date:  2021-07-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.